This HTML5 document contains 47 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n11http://linked.opendata.cz/resource/drugbank/drug/DB01388/identifier/chemspider/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01388/identifier/wikipedia/
n6http://linked.opendata.cz/resource/drugbank/drug/DB01388/identifier/pharmgkb/
n17http://bio2rdf.org/drugbank:
n10http://linked.opendata.cz/resource/drugbank/drug/DB01388/identifier/bindingdb/
n9http://linked.opendata.cz/resource/drugbank/drug/DB01388/identifier/kegg-compound/
n7http://linked.opendata.cz/resource/drugbank/drug/DB01388/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n15http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01388/identifier/pubchem-substance/
n8http://linked.opendata.cz/resource/drugbank/drug/DB01388/identifier/drugbank/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB01388
rdf:type
n3:Drug
n3:description
Mibefradil was withdrawn from the market in 1998 because of potentially harmful interactions with other drugs.
n3:group
withdrawn
n3:halfLife
17 to 25 hours at steady state.
n3:indication
For the treatment of angina and high blood pressure.
owl:sameAs
n15:DB01388 n17:DB01388
dcterms:title
Mibefradil
adms:identifier
n6:PA450492 n7:60663 n8:DB01388 n9:C07222 n10:50117922 n11:54673 n12:Mibefradil n13:46504498
n3:mechanismOfAction
Mibefradil is a tetralol calcium channel blocking agent that inhibits the influx of calcium ions across both the T (low-voltage) and L (high-voltage) calcium channels of cardiac and vascular smooth muscle, with a greater selectivity for T channels. Vasodilation occurs in vascular smooth muscle, causing a decrease in peripheral vascular resistance and a resulting decrease in blood pressure. Mibefradil causes a slight increase in cardiac output during chronic dosing. Mibefradil slows sinus and atrioventricular (AV) node conduction, producing a slight reduction in heart rate and a slight increase in the PR interval. It has also been shown to slightly lengthen the corrected sinus node recovery time and AH interval and to raise the Wenckebach point. The mechanism by which mibefradil reduces angina is not known, but is thought to be attributed to a reduction in heart rate, total peripheral resistance (afterload), and the heart rate–systolic blood pressure product at any given level of exercise. The result of these effects is a decrease in cardiac workload and myocardial oxygen demand.
n3:proteinBinding
≥ 99%, primarily to alpha 1-acid glycoprotein.
n3:IUPAC-Name
n4:271B4461-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4467-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4466-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4463-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4464-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4465-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B445F-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B445D-363D-11E5-9242-09173F13E4C5 n4:271B4460-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B445E-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B446C-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B446D-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4468-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4469-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B446A-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B446B-363D-11E5-9242-09173F13E4C5
n3:absorption
Bioavailability after a single dose is 70%. After multiple dosing, the proportion of mibefradil undergoing first-pass metabolism is reduced, resulting in a steady state bioavailability of approximately 90%. Food does not affect the rate or extent of absorption of mibefradil.
n3:affectedOrganism
Humans and other mammals
n3:caco2-Permeability
n4:271B4476-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
116644-53-2
n3:Bioavailability
n4:271B4472-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4474-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4475-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4471-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4470-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4473-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4462-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B446E-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B446F-363D-11E5-9242-09173F13E4C5